{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:44:32Z","timestamp":1789789472792,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1153493"],"award-info":[{"award-number":["APP1153493"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1157643"],"award-info":[{"award-number":["APP1157643"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2007920"],"award-info":[{"award-number":["APP2007920"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007224","name":"National Foundation for Science and Technology Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"The University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40262-026-01619-3","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:01:29Z","timestamp":1770710489000},"page":"583-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single Saliva Sample Model-Informed Precision Dosing of Levofloxacin for Multidrug-Resistant Tuberculosis"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8508-8990","authenticated-orcid":false,"given":"Thi A.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-0223","authenticated-orcid":false,"given":"Tri P.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luong V.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-6716","authenticated-orcid":false,"given":"Hoa D.","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tram N. B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dang","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-587X","authenticated-orcid":false,"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"1619_CR1","unstructured":"WHO. Global tuberculosis report 2024 [Internet]. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024. Accessed 12 May 2025"},{"key":"1619_CR2","unstructured":"WHO. WHO issues rapid communication on key updates to the treatment of drug-resistant tuberculosis [Internet]. https:\/\/www.who.int\/news\/item\/23-08-2024-who-issues-rapid-communication-on-key-updates-to-the-treatment-of-drug-resistant-tuberculosis. Accessed 12 May 2025"},{"key":"1619_CR3","unstructured":"WHO. WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. WHO Guidelines Approved by the Guidelines Review Committee. Geneva 2022."},{"key":"1619_CR4","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1093\/cid\/ciy611","volume":"67","author":"D Deshpande","year":"2018","unstructured":"Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, et al. Levofloxacin Pharmacokinetics\/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. Clin Infect Dis. 2018;67:S293-302. https:\/\/doi.org\/10.1093\/cid\/ciy611.","journal-title":"Clin Infect Dis"},{"key":"1619_CR5","doi-asserted-by":"crossref","unstructured":"Capiau S, Alffenaar J, Stove C. Alternative sampling strategies for therapeutic drug monitoring. In: Clinical Challenges in therapeutic drug monitoring. Elsevier; 2016. p. 279\u2013323.","DOI":"10.1016\/B978-0-12-802025-8.00013-1"},{"key":"1619_CR6","unstructured":"InsightRX. InsightRX Nova: Precision dosing platform [Internet]. https:\/\/insight-rx.com\/."},{"key":"1619_CR7","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s11096-019-00886-4","volume":"41","author":"ML Avent","year":"2019","unstructured":"Avent ML, Rogers BA. Optimising antimicrobial therapy through the use of Bayesian dosing programs. Int J Clin Pharm. 2019;41:1121\u201330. https:\/\/doi.org\/10.1007\/s11096-019-00886-4.","journal-title":"Int J Clin Pharm"},{"key":"1619_CR8","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1128\/AAC.00341-15","volume":"59","author":"A Alsultan","year":"2015","unstructured":"Alsultan A, An G, Peloquin CA. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis. Antimicrob Agents Chemother. 2015;59:3800\u20137. https:\/\/doi.org\/10.1128\/AAC.00341-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"1619_CR9","doi-asserted-by":"publisher","first-page":"e01092","DOI":"10.1128\/AAC.01092-18","volume":"62","author":"SHJ van den Elsen","year":"2018","unstructured":"van den Elsen SHJ, Sturkenboom MGG, Van\u2019T Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, et al. Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. Antimicrob Agents Chemother. 2018;62:e01092-e1118. https:\/\/doi.org\/10.1128\/AAC.01092-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1619_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40262-024-01346-7","volume":"63","author":"L Davies Forsman","year":"2024","unstructured":"Davies Forsman L, Kim HY, Nguyen TA, Alffenaar J-WC. Salivary therapeutic drug monitoring of antimicrobial therapy: feasible or futile? Clin Pharmacokinet. 2024;63:269\u201378. https:\/\/doi.org\/10.1007\/s40262-024-01346-7.","journal-title":"Clin Pharmacokinet"},{"key":"1619_CR11","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1093\/cid\/ciz942","volume":"70","author":"J-WC Alffenaar","year":"2020","unstructured":"Alffenaar J-WC, Gumbo T, Dooley KE, Peloquin CA, Mcilleron H, Zagorski A, et al. Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis. Clin Infect Dis. 2020;70:1774\u201380. https:\/\/doi.org\/10.1093\/cid\/ciz942.","journal-title":"Clin Infect Dis"},{"key":"1619_CR12","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40262-024-01398-9","volume":"63","author":"TA Nguyen","year":"2024","unstructured":"Nguyen TA, Chen RH, Hawkins BA, Hibbs DE, Kim HY, Wheate NJ, et al. Can we predict drug excretion into saliva? A systematic review and analysis of physicochemical properties. Clin Pharmacokinet. 2024;63:1067\u201387. https:\/\/doi.org\/10.1007\/s40262-024-01398-9.","journal-title":"Clin Pharmacokinet"},{"key":"1619_CR13","unstructured":"Drug Bank. Levofloxacin [Internet]. https:\/\/go.drugbank.com\/drugs\/DB01137."},{"key":"1619_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02379-18","volume":"63","author":"S Ghimire","year":"2019","unstructured":"Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, et al. Evaluation of saliva as a potential alternative sampling matrix for therapeutic drug monitoring of levofloxacin in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2019;63:e02379-18. https:\/\/doi.org\/10.1128\/AAC.02379-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1619_CR15","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/jac\/dkab057","volume":"76","author":"S Mohamed","year":"2021","unstructured":"Mohamed S, Mvungi HC, Sariko M, Rao P, Mbelele P, Jongedijk EM, et al. Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. J Antimicrob Chemother. 2021;76:1547\u201352. https:\/\/doi.org\/10.1093\/jac\/dkab057.","journal-title":"J Antimicrob Chemother"},{"key":"1619_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/jac\/dkaa420","volume":"76","author":"J-WC Alffenaar","year":"2021","unstructured":"Alffenaar J-WC, Jongedijk EM, Van Winkel CAJ, Sariko M, Heysell SK, Mpagama S, et al. A mobile microvolume UV\/visible light spectrophotometer for the measurement of levofloxacin in saliva. J Antimicrob Chemother. 2021;76:423\u20139. https:\/\/doi.org\/10.1093\/jac\/dkaa420.","journal-title":"J Antimicrob Chemother"},{"key":"1619_CR17","doi-asserted-by":"publisher","unstructured":"Sprague DA, Ensom MHH. Limited-sampling strategies for anti-infective agents: systematic review. CJHP [Internet]. 2009;62. https:\/\/doi.org\/10.4212\/cjhp.v62i5.827","DOI":"10.4212\/cjhp.v62i5.827"},{"key":"1619_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.70051","volume":"8","author":"TA Nguyen","year":"2025","unstructured":"Nguyen TA, Nath CE, Rosser SPA, Stocker SL, Alffenaar JC. Simultaneous quantification of levofloxacin and linezolid in human plasma and saliva using liquid chromatography quadrupole\u2010orbitrap mass spectrometry. SEPARATION SCIENCE PLUS. 2025;8:e70051. https:\/\/doi.org\/10.1002\/sscp.70051.","journal-title":"SEPARATION SCIENCE PLUS"},{"key":"1619_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2013.24","volume":"2","author":"R Keizer","year":"2013","unstructured":"Keizer R, Karlsson M, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:1\u20139. https:\/\/doi.org\/10.1038\/psp.2013.24.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1619_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85\u201394. https:\/\/doi.org\/10.1016\/j.cmpb.2003.11.003.","journal-title":"Comput Methods Programs Biomed"},{"key":"1619_CR21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1128\/AAC.01036-07","volume":"52","author":"CA Peloquin","year":"2008","unstructured":"Peloquin CA, Hadad DJ, Molino LPD, Palaci M, Boom WH, Dietze R, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:852\u20137. https:\/\/doi.org\/10.1128\/AAC.01036-07.","journal-title":"Antimicrob Agents Chemother"},{"key":"1619_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bcp.12783","volume":"81","author":"L Kervezee","year":"2016","unstructured":"Kervezee L, Stevens J, Birkhoff W, Kamerling IMC, De Boer T, Dr\u00f6ge M, et al. Identifying 24 h variation in the pharmacokinetics of levofloxacin: a population pharmacokinetic approach. Br J Clin Pharmacol. 2016;81:256\u201368. https:\/\/doi.org\/10.1111\/bcp.12783.","journal-title":"Br J Clin Pharmacol"},{"key":"1619_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ijantimicag.2013.04.028","volume":"42","author":"P Kontou","year":"2013","unstructured":"Kontou P, Manika K, Chatzika K, Papaioannou M, Sionidou M, Pitsiou G, et al. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. Int J Antimicrob Agents. 2013;42:262\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.04.028.","journal-title":"Int J Antimicrob Agents"},{"key":"1619_CR24","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1128\/AAC.02610-15","volume":"60","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Cotta MO, Cojutti P, Lugano M, Rocca GD, Pea F. Does critical illness change levofloxacin pharmacokinetics? Antimicrob Agents Chemother. 2016;60:1459\u201363. https:\/\/doi.org\/10.1128\/AAC.02610-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"1619_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/bdd.2294","volume":"42","author":"A Boonpeng","year":"2021","unstructured":"Boonpeng A, Jaruratanasirikul S, Wattanavijitkul T, Nawakitrangsan M, Samaeng M. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug\u2010resistant tuberculosis therapy. Biopharm Drug Dispos. 2021;42:329\u201337. https:\/\/doi.org\/10.1002\/bdd.2294.","journal-title":"Biopharm Drug Dispos"},{"key":"1619_CR26","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1111\/bcp.15823","volume":"89","author":"A Samb","year":"2023","unstructured":"Samb A, Sinkeler F, Bijleveld YA, Van Kaam A, De Haan TR, Math\u00f4t R. Therapeutic drug monitoring of amikacin in preterm and term neonates with late\u2010onset sepsis. Can saliva samples replace plasma samples? Br J Clin Pharmacol. 2023;89:3195\u2013203. https:\/\/doi.org\/10.1111\/bcp.15823.","journal-title":"Br J Clin Pharmacol"},{"key":"1619_CR27","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/jcph.1445","volume":"59","author":"SG Wicha","year":"2019","unstructured":"Wicha SG, Mundkowski RG, Klock A, Hopt UT, Drewelow B, Kloft C, et al. Is moxifloxacin a treatment option for pancreatic infections? A pharmacometric analysis of serum and pancreatic juice. J Clin Pharmacol. 2019;59:1405\u201314. https:\/\/doi.org\/10.1002\/jcph.1445.","journal-title":"J Clin Pharmacol"},{"key":"1619_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25\u201336. https:\/\/doi.org\/10.2133\/dmpk.24.25.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1619_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094708.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1619_CR30","unstructured":"Holford N. The Visual Predictive Check \u2013 Superiority to Standard Diagnostic (Rorschach) Plot. Pamplona, Spain; 2005. www.page-meeting.org\/?abstract=738."},{"key":"1619_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","volume":"44","author":"A-G Dosne","year":"2017","unstructured":"Dosne A-G, Bergstrand M, Karlsson MO. An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn. 2017;44:509\u201320. https:\/\/doi.org\/10.1007\/s10928-017-9542-0.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1619_CR32","unstructured":"U.S. Food and Drug Administration. Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application [Internet]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug."},{"key":"1619_CR33","unstructured":"European Medicines Agency. Guideline on the Investigation of Bioequivalence. [Internet]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf."},{"key":"1619_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01521-17","volume":"62","author":"P Denti","year":"2018","unstructured":"Denti P, Garcia-Prats AJ, Draper HR, Wiesner L, Winckler J, Thee S, et al. Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2018;62:e01521-17. https:\/\/doi.org\/10.1128\/AAC.01521-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1619_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01865-18","volume":"63","author":"AJ Garcia-Prats","year":"2019","unstructured":"Garcia-Prats AJ, Purchase SE, Osman M, Draper HR, Schaaf HS, Wiesner L, et al. Pharmacokinetics, safety, and dosing of novel pediatric levofloxacin dispersible tablets in children with multidrug-resistant tuberculosis exposure. Antimicrob Agents Chemother. 2019;63:e01865-18. https:\/\/doi.org\/10.1128\/AAC.01865-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1619_CR36","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/cid\/ciae024","volume":"78","author":"YN White","year":"2024","unstructured":"White YN, Solans BP, Denti P, Van Der Laan LE, Schaaf HS, Vonasek B, et al. Pharmacokinetics and optimal dosing of levofloxacin in children for drug-resistant tuberculosis: an individual patient data meta-analysis. Clin Infect Dis. 2024;78:756\u201364. https:\/\/doi.org\/10.1093\/cid\/ciae024.","journal-title":"Clin Infect Dis"},{"key":"1619_CR37","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558\u201369. https:\/\/doi.org\/10.1208\/s12248-009-9133-0.","journal-title":"AAPS J"},{"key":"1619_CR38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1208\/s12248-012-9387-9","volume":"14","author":"PL Bonate","year":"2012","unstructured":"Bonate PL, Strougo A, Desai A, Roy M, Yassen A, Van Der Walt JS, et al. Guidelines for the quality control of population pharmacokinetic\u2013pharmacodynamic analyses: an industry perspective. AAPS J. 2012;14:749\u201358. https:\/\/doi.org\/10.1208\/s12248-012-9387-9.","journal-title":"AAPS J"},{"key":"1619_CR39","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1093\/jac\/dkw164","volume":"71","author":"S Ghimire","year":"2016","unstructured":"Ghimire S, Van\u2019T Boveneind-Vrubleuskaya N, Akkerman OW, De Lange WCM, Van Soolingen D, Kosterink JGW, et al. Pharmacokinetic\/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. J Antimicrob Chemother. 2016;71:2691\u2013703. https:\/\/doi.org\/10.1093\/jac\/dkw164.","journal-title":"J Antimicrob Chemother"},{"key":"1619_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00343-17","volume":"61","author":"N Van\u2019T Boveneind-Vrubleuskaya","year":"2017","unstructured":"Van\u2019T Boveneind-Vrubleuskaya N, Seuruk T, Van Hateren K, Van Der Laan T, Kosterink JGW, Van Der Werf TS, et al. Pharmacokinetics of levofloxacin in multidrug- and extensively drug-resistant tuberculosis patients. Antimicrob Agents Chemother. 2017;61:e00343-17. https:\/\/doi.org\/10.1128\/AAC.00343-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1619_CR41","unstructured":"WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment [Internet]. Geneva; https:\/\/www.who.int\/publications\/i\/item\/9789241550529. Accessed 19 June 2025."},{"key":"1619_CR42","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","volume":"200","author":"P Nahid","year":"2019","unstructured":"Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of Drug-resistant tuberculosis. An Official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200:e93-142. https:\/\/doi.org\/10.1164\/rccm.201909-1874ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"1619_CR43","unstructured":"Centers for Disease Control and Prevention (CDC). Core Curriculum on Tuberculosis: What the Clinician Should Know [Internet]. https:\/\/www.cdc.gov\/tb\/education\/corecurr\/. Accessed 19 June 2025."},{"key":"1619_CR44","unstructured":"WHO. Compendium of WHO guidelines and associated standards: ensuring\u202foptimum delivery of the cascade of care for patients with tuberculosis [Internet]. https:\/\/www.who.int\/publications\/i\/item\/9789241514101. Accessed 19 June 2025."},{"key":"1619_CR45","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02107-2018","volume":"53","author":"S Ghimire","year":"2019","unstructured":"Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, et al. Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients. Eur Respir J. 2019;53:1802107. https:\/\/doi.org\/10.1183\/13993003.02107-2018.","journal-title":"Eur Respir J"},{"key":"1619_CR46","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1164\/rccm.202407-1354OC","volume":"211","author":"PPJ Phillips","year":"2025","unstructured":"Phillips PPJ, Peloquin CA, Sterling TR, Kaur P, Diacon AH, Gotuzzo E, et al. Efficacy and safety of higher doses of levofloxacin for multidrug-resistant tuberculosis: a randomized, placebo-controlled phase II clinical trial. Am J Respir Crit Care Med. 2025;211:1277\u201387. https:\/\/doi.org\/10.1164\/rccm.202407-1354OC.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01619-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01619-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01619-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:25:58Z","timestamp":1774963558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01619-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1619"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01619-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants prior to study enrolment, in accordance with the approved protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The model codes that support the findings of this study can be accessible in Table\n                      \n                      , Supplementary Material.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Available"}},{"value":"The data supporting this study's findings may be available on request from the principal investigator of the study (J.W. Alffenaar).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Ethical approval was granted by the University of Sydney, Australia (Protocol No. 2021\/082, dated 21.10.2021) and the National Lung Hospital, Vietnam (Approval No. 25\/21\/CN-HDDD, dated 27\/04\/2021).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"T.A. Nguyen conceptualised the study, performed drug concentration analysis, performed the pharmacometrics data analyses and wrote the manuscript. T.P. Nguyen performed the pharmacometrics data analyses and revised the manuscript. A.T. Nguyen revised the manuscript. L.V. Dinh revised the manuscript. B.H. Nguyen revised the manuscript. D.H. Vu revised the manuscript. T.N.B. Nguyen revised the manuscript. D. Vu revised the manuscript. G.J. Fox conceptualised the study and revised the manuscript. J.W. Alffenaar conceptualised the study, supervised the analysis and revised the manuscript. S.L. Stocker conceptualised the study, supervised the analysis and revised the manuscript. All authors revised the manuscript and accepted submission to the journal.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Jan-Willem C. Alffenaar and Sophie L. Stocker are Editorial Board members of\n                      Clinical Pharmacokinetics\n                      . They were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The others declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}